Empirically derived profiles of neurocognitive functioning in youth and young adults with sickle cell disease.
Saved in:
| Title: | Empirically derived profiles of neurocognitive functioning in youth and young adults with sickle cell disease. |
|---|---|
| Authors: | Ellison, Vinkrya1,2,3 (AUTHOR), Berlin, Kristoffer S2,3 (AUTHOR), Longoria, Jennifer1 (AUTHOR), Potter, Brian1 (AUTHOR), Raches, Darcy1 (AUTHOR), Hankins, Jane S4,5 (AUTHOR), Takemoto, Clifford4 (AUTHOR), Heitzer, Andrew M1 (AUTHOR) aheitzer@stjude.org |
| Source: | Journal of Pediatric Psychology. Sep2024, Vol. 49 Issue 9, p605-613. 9p. |
| Subject Terms: | *Young adults, *Cognitive development, *Individual development, Sickle cell anemia, Membership functions (Fuzzy logic) |
| Abstract: | Objective Sickle cell disease (SCD) is an inherited blood disorder associated with neurocognitive deficits. In contrast to variable-centered approaches, no known research has utilized person-centered strategies to identify multidimensional patterns of neurocognitive functioning of an individual with SCD. The purpose of the present study was to create empirically derived profiles and identify predictors of neurocognitive functioning subgroups among youth and young adults with SCD. Methods Individuals with SCD (N = 393, mean age 14.05 years, age range 8–24, 50.4% female/49.6% male) completed neurocognitive assessments. Latent profile analysis derived subgroups/classes of neurocognitive functioning and determined relations with demographic and medical variables. Results Three latent classes emerged: average functioning (n = 102, 27%), low average functioning (n = 225, 60%), and exceptionally low functioning (n = 46, 12%). Older age was associated with membership in the low average and exceptionally low functioning groups (relative to the average group). Being prescribed hydroxyurea was associated with membership in the average functioning group (relative to the low average group) and absence of hydroxyurea use was associated with membership in the exceptionally low group (relative to the low average group). Lower social vulnerability was associated with membership in the average functioning group compared to the low average and exceptionally low groups. Conclusions Clinicians can help reduce disparities in cognitive development for individuals with SCD by promoting early treatment with hydroxyurea and implementing methods to reduce social vulnerabilities that can interfere with access to evidence-based care. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Pediatric Psychology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Education Research Complete |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objective Sickle cell disease (SCD) is an inherited blood disorder associated with neurocognitive deficits. In contrast to variable-centered approaches, no known research has utilized person-centered strategies to identify multidimensional patterns of neurocognitive functioning of an individual with SCD. The purpose of the present study was to create empirically derived profiles and identify predictors of neurocognitive functioning subgroups among youth and young adults with SCD. Methods Individuals with SCD (N = 393, mean age 14.05 years, age range 8–24, 50.4% female/49.6% male) completed neurocognitive assessments. Latent profile analysis derived subgroups/classes of neurocognitive functioning and determined relations with demographic and medical variables. Results Three latent classes emerged: average functioning (n = 102, 27%), low average functioning (n = 225, 60%), and exceptionally low functioning (n = 46, 12%). Older age was associated with membership in the low average and exceptionally low functioning groups (relative to the average group). Being prescribed hydroxyurea was associated with membership in the average functioning group (relative to the low average group) and absence of hydroxyurea use was associated with membership in the exceptionally low group (relative to the low average group). Lower social vulnerability was associated with membership in the average functioning group compared to the low average and exceptionally low groups. Conclusions Clinicians can help reduce disparities in cognitive development for individuals with SCD by promoting early treatment with hydroxyurea and implementing methods to reduce social vulnerabilities that can interfere with access to evidence-based care. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 01468693 |
| DOI: | 10.1093/jpepsy/jsae029 |
